Abstract：Objective To investigate the efficacy and safety of different doses of recombinant human growth hormone (rhGH) in the treatment of short stature in children born small for gestational age (SGA). Methods A total of 37 children with short stature born SGA were enrolled, and based on the dose of rhGH treatment, they were divided into low-dose rhGH group (0.1-0.15 IU/kg daily) and high-dose rhGH group (0.16-0.2 IU/kg daily). The changes in height standard deviation score (ΔHtSDS), height velocity (HV), serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and fasting blood glucose at 3, 6, 9, 12, and 24 months after treatment were compared between the two groups. Results ΔHtSDS and HV both increased after the treatment with high-and low-dose rhGH, but ΔHtSDS and HV in the high-dose rhGH group were significantly higher than in the lowdose rhGH group 9, 12 and 24 months after treatment (PConclusions rhGH has good efficacy in the treatment of short stature in children born SGA, with few adverse events, and high-dose rhGH has some advantages over low-dose rhGH.
QIE Di,YANG Fan. Efficacy of different doses of recombinant human growth hormone in the treatment of short stature in children born small for gestational age[J]. CJCP, 2016, 18(3): 247-253.
De Zegher F, Hokken Koelega A. Growth hormone therapy for children born small for gestational age: high gain is less dose dependent over the long term than over the short term[J]. Pediatrics, 2005, 115(4): e458-462.
Hokken-Koelega A, van Pareren Y, Arends N. Effects of growth hormone treatment on cognitive function and head circumference in children born small for gestational age[J]. Horm Res, 2005, 64(Suppl 3): S95-S99.
de Zegher F, Albertsson-Wikland K, Wollmann HA, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years[J]. J Clin Endocrinol Metab, 2000, 85(8): 2816-2821.
[10]
Van Pareren Y, Mulder P, Houdijk M, et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial[J]. J Clin Endocrinol Metab, 2003, 88(8): 3584-3590.
[11]
Maiorana A, Cianfarani S. Impact of growth hormone therapy on adult height of children born small for gestational age[J]. Pediatrics, 2009,124(3): e519-e531.
[12]
Carel JC, Chatelain P, Rochiccioli P, et al. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study[J]. J Clin Endocrinol Metab, 2003, 88(4): 1587-1593.
[13]
van Dijk M1, Bannink EM, van Pareren YK, et al. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls[J]. J Clin Endocrinol Metab, 2007, 92(1): 160-165.
[14]
Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during longterm growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency[J]. J Clin Endocrinol Metab, 2000, 85(10): 3786-3792.
[15]
Saenger P, Reiter E. Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder [J/OL]. Int J Pediatr Endocrinol, 2012, 2012(1): 12.
[16]
Klammt J, Kiess W, Pfäffle R. IGF-1R mutations as cause of SGA[J]. Best Pract Res Clin Endocrinol Metab, 2011, 25(1): 191-206.
[17]
Leal Ade C, Canton AP, Montenegro LR, et al. Mutations in insulin-like growth factor receptor 1 gene (IGF-1R) resulting in intrauterine and postnatal growth retardation[J]. Arq Bras Endocrinol Metabol, 2011, 55(8): 541-549.
[18]
Trivin C, Souberbielle JC, Aubertin G, et a1. Diagnosis of idiopathic growth hormone deficiency: contributions of data on the acid-labile subunit, insulin-like growth factor (IGF)-I and -II, and IGF binding protein-3[J]. J Pediatr Endocrinol Metab, 2006, 19(4): 481-489.
Hales CN, Desai M, Ozanne SE. The thrifty phenotype hypothesis: how does it look after 5 years?[J]. Diabet Med, 1997, 14(3): 189-195.
[21]
Bell J, Parker KL, Swinford RD, et a1. Long-term safety of recombinant human growth hormone in children[J]. J Clin Endocrinol Metab, 2010, 95(1): 167-177.
